Abstract
With demonstration of effective therapies for advanced cSCC, and as immunotherapy in the adjuvant setting is being considered, accurate prognosis is critical. A prognostic 40-gene expression profile (40-GEP) test was recently validated using an independent cohort of cSCC patients with ≥1 risk factors to accurately classify patients as low (Class 1), moderate (Class 2A), or high risk (Class 2B) for metastasis. Ongoing prospective clinical validation and utility studies are discussed. This analysis evaluated impact of 40-GEP risk stratification as enrollment criteria into adjuvant therapy trial design.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
